Cargando…

Subtyping of sarcomas based on pathway enrichment scores in bulk and single cell transcriptomes

BACKGROUND: Sarcomas are highly heterogeneous in molecular, pathologic, and clinical features. However, a classification of sarcomas by integrating different types of pathways remains mostly unexplored. METHODS: We performed hierarchical clustering analysis of sarcomas based on the enrichment scores...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Shengwei, Liu, Qian, Zhou, Haiying, Lu, Hui, Wang, Xiaosheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800234/
https://www.ncbi.nlm.nih.gov/pubmed/35093080
http://dx.doi.org/10.1186/s12967-022-03248-3
_version_ 1784642215760363520
author Li, Shengwei
Liu, Qian
Zhou, Haiying
Lu, Hui
Wang, Xiaosheng
author_facet Li, Shengwei
Liu, Qian
Zhou, Haiying
Lu, Hui
Wang, Xiaosheng
author_sort Li, Shengwei
collection PubMed
description BACKGROUND: Sarcomas are highly heterogeneous in molecular, pathologic, and clinical features. However, a classification of sarcomas by integrating different types of pathways remains mostly unexplored. METHODS: We performed hierarchical clustering analysis of sarcomas based on the enrichment scores of 14 pathways involved in immune, stromal, DNA damage repair (DDR), and oncogenic signatures in three bulk tumor transcriptome datasets. RESULTS: Consistently in the three datasets, sarcomas were classified into three subtypes: Immune Class (Imm-C), Stromal Class (Str-C), and DDR Class (DDR-C). Imm-C had the strongest anti-tumor immune signatures and the lowest intratumor heterogeneity (ITH); Str-C showed the strongest stromal signatures, the highest genomic stability and global methylation levels, and the lowest proliferation potential; DDR-C had the highest DDR activity, expression of the cell cycle pathway, tumor purity, stemness scores, proliferation potential, and ITH, the most frequent TP53 mutations, and the worst survival. We further validated the stability and reliability of our classification method by analyzing a single cell RNA-Seq (scRNA-seq) dataset. Based on the expression levels of five genes in the pathways of T cell receptor signaling, cell cycle, mismatch repair, focal adhesion, and calcium signaling, we built a linear risk scoring model (ICMScore) for sarcomas. We demonstrated that ICMScore was an adverse prognostic factor for sarcomas and many other cancers. CONCLUSIONS: Our classification method provides novel insights into tumor biology and clinical implications for sarcomas. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-022-03248-3.
format Online
Article
Text
id pubmed-8800234
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-88002342022-02-02 Subtyping of sarcomas based on pathway enrichment scores in bulk and single cell transcriptomes Li, Shengwei Liu, Qian Zhou, Haiying Lu, Hui Wang, Xiaosheng J Transl Med Research BACKGROUND: Sarcomas are highly heterogeneous in molecular, pathologic, and clinical features. However, a classification of sarcomas by integrating different types of pathways remains mostly unexplored. METHODS: We performed hierarchical clustering analysis of sarcomas based on the enrichment scores of 14 pathways involved in immune, stromal, DNA damage repair (DDR), and oncogenic signatures in three bulk tumor transcriptome datasets. RESULTS: Consistently in the three datasets, sarcomas were classified into three subtypes: Immune Class (Imm-C), Stromal Class (Str-C), and DDR Class (DDR-C). Imm-C had the strongest anti-tumor immune signatures and the lowest intratumor heterogeneity (ITH); Str-C showed the strongest stromal signatures, the highest genomic stability and global methylation levels, and the lowest proliferation potential; DDR-C had the highest DDR activity, expression of the cell cycle pathway, tumor purity, stemness scores, proliferation potential, and ITH, the most frequent TP53 mutations, and the worst survival. We further validated the stability and reliability of our classification method by analyzing a single cell RNA-Seq (scRNA-seq) dataset. Based on the expression levels of five genes in the pathways of T cell receptor signaling, cell cycle, mismatch repair, focal adhesion, and calcium signaling, we built a linear risk scoring model (ICMScore) for sarcomas. We demonstrated that ICMScore was an adverse prognostic factor for sarcomas and many other cancers. CONCLUSIONS: Our classification method provides novel insights into tumor biology and clinical implications for sarcomas. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-022-03248-3. BioMed Central 2022-01-29 /pmc/articles/PMC8800234/ /pubmed/35093080 http://dx.doi.org/10.1186/s12967-022-03248-3 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Li, Shengwei
Liu, Qian
Zhou, Haiying
Lu, Hui
Wang, Xiaosheng
Subtyping of sarcomas based on pathway enrichment scores in bulk and single cell transcriptomes
title Subtyping of sarcomas based on pathway enrichment scores in bulk and single cell transcriptomes
title_full Subtyping of sarcomas based on pathway enrichment scores in bulk and single cell transcriptomes
title_fullStr Subtyping of sarcomas based on pathway enrichment scores in bulk and single cell transcriptomes
title_full_unstemmed Subtyping of sarcomas based on pathway enrichment scores in bulk and single cell transcriptomes
title_short Subtyping of sarcomas based on pathway enrichment scores in bulk and single cell transcriptomes
title_sort subtyping of sarcomas based on pathway enrichment scores in bulk and single cell transcriptomes
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800234/
https://www.ncbi.nlm.nih.gov/pubmed/35093080
http://dx.doi.org/10.1186/s12967-022-03248-3
work_keys_str_mv AT lishengwei subtypingofsarcomasbasedonpathwayenrichmentscoresinbulkandsinglecelltranscriptomes
AT liuqian subtypingofsarcomasbasedonpathwayenrichmentscoresinbulkandsinglecelltranscriptomes
AT zhouhaiying subtypingofsarcomasbasedonpathwayenrichmentscoresinbulkandsinglecelltranscriptomes
AT luhui subtypingofsarcomasbasedonpathwayenrichmentscoresinbulkandsinglecelltranscriptomes
AT wangxiaosheng subtypingofsarcomasbasedonpathwayenrichmentscoresinbulkandsinglecelltranscriptomes